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Abstract: Lupus nephritis is a complication of systemic lupus erythematosus, which has sig-
niﬁ  cant morbidity and mortality. The accepted standard of treatment for severe lupus nephritis 
is cyclophosphamide for induction of remission. This has signiﬁ  cant adverse effects including 
severe infection and amenorrhea. In addition, although cyclophosphamide induces remission, 
long-term mortality does not seem to be altered. Mycophenolate mofetil (MMF) is an immuno-
suppressive agent originally used in solid organ transplantation, which has been compared with 
cyclophosphamide in trials for lupus nephritis. Randomized trials with MMF have been relatively 
small, although pooled data seem to suggest that it is at least as effective as cyclophosphamide in 
inducing remission. In addition, MMF has also been associated with a reduced risk of infection 
and amenorrhea, although this ﬁ  nding is not universal. MMF appears to be associated with more 
diarrhea compared with cyclophosphamide. MMF is likely to be a useful treatment for lupus 
nephritis, although available trial data are limited due to the small size of previous studies. A 
large trial (the Aspreva Lupus Management Study) is currently underway to attempt to establish 
the place of MMF in treatment of lupus nephritis.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease which 
can manifest in a variety of ways. Patients with SLE can present with photosensitivity, 
skin rashes, arthritis, cytopenias, and neurological involvement and frequently pos-
sess a plethora of antibodies directed against various components in the cell nucleus, 
particularly double stranded DNA. In a signiﬁ  cant number of patients, SLE can cause 
nephritis that can result in renal failure with signiﬁ  cant morbidity and mortality. Both 
the prevalence and severity of SLE varies with age, gender, and ethnicity (Danchenko 
et al 2006). Women of childbearing age are most likely to be affected with SLE. In 
addition, African and Hispanic ethnicity has been associated with greater prevalence 
and severity of disease (Bastian et al 2002). This study showed that Caucasians had a 
14% cumulative incidence of nephritis compared with 51% in African-Americans and 
43% in Hispanics. Another study showed that 10% of Caucasian patients compared 
with 27% of Indo-Asian and 58% of Afro-Caribbean patients had biopsy proven 
nephritis (Patel et al 2006).
The assessment of lupus nephritis has improved recently with the updated histological 
WHO classiﬁ  cation by the International Society of Nephrology and the Renal Pathology 
Society (Weening et al 2004). The updated classiﬁ  cation deﬁ  ned class I nephritis as 
normal glomeruli by light microscopy but with mesangial immune deposits by immu-
noﬂ  uorescence; class II as mesangial immune deposits with mesangial hypercellularity; 
class III as focal glomerulonephritis involving 50% of glomeruli with subdivisions 
for active and sclerotic lesions; class IV nephritis as diffuse glomerulonephritis with 
50% of total glomeruli affected; class V as membranous lupus nephritis; and class Biologics: Targets & Therapy 2008:2(2) 298
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VI as advanced-stage lupus nephritis with 90% global 
glomerulosclerosis. Class IV nephritis was further divided into 
class IV-S and IV-G with segmental and global involvement as 
well as subdivisions for active and sclerotic lesions. Classes 
III, IV, and V are associated with poorer prognoses than Class 
I and II and usually require active intervention (Yokoyama et al 
2004). This updated classiﬁ  cation has allowed more meaning-
ful comparison of histological specimens between various 
centers and standardization of clinical trials by improving 
reproducibility in classiﬁ  cation (Yokoyama et al 2004; Furness 
and Taub 2006), although at present all published controlled 
trials were classiﬁ  ed using the previous system.
Treatment of severe lupus nephritis usually comprises 
an induction phase and a maintenance phase. The current 
accepted standard of care for treatment of proliferative lupus 
nephritis is monthly high-dose intravenous cyclophospha-
mide for induction. This regimen was developed in the 1970s 
and 1980s following trials by the US National Institutes 
of Health (NIH) (Austin et al 1986; Boumpas et al 1992; 
Gourley et al 1996). However, a meta-analysis showed that 
although treatment with cyclophosphamide reduced the risk 
of doubling of serum creatinine, overall mortality was not 
altered and there was no signiﬁ  cant reduction in the risk of 
end-stage renal failure (although there was a trend towards 
better outcomes with cyclophosphamide) (Flanc et al 2004). 
In addition, these trials included predominantly Caucasian 
patients despite the higher incidence and severity of lupus 
nephritis in non-Caucasian populations as well as excluding 
patients with severely impaired renal function; thus limiting 
their application to a more generalized lupus nephritis cohort. 
High-dose cyclophosphamide is also associated with signiﬁ  -
cant adverse effects including an increased infection risk, 
sterility, secondary malignancy, and hemorrhagic cystitis.
In the 1950s patients with proliferative lupus nephritis 
rarely lived beyond 5 years (Cameron 1999). This has 
improved, although cohort studies done between 1992 and 
2001 demonstrate that the outcomes in lupus nephritis are 
still relatively poor. These showed a 5-year mortality of 
almost 15% and a 10-year mortality of almost 25% (Trager 
and Ward 2001). The rates of end-stage renal disease were 
12% at 5 years and approximately 25% at 10 years. These 
data are signiﬁ  cant as they represent “real world” outcomes 
outside highly specialized centers and suggest that there is 
still signiﬁ  cant ground for improvement of care.
On the background described above, various alternative 
strategies have been researched in the context of lupus nephri-
tis. Alternative cyclophosphamide regimens have been tried 
and Houssiau and colleagues compared high dose intravenous 
cyclophosphamide given monthly for 6 months followed 
by a further 2 doses 3 months apart (46 patients) against a 
regimen with six ﬁ  xed-doses of 500 mg cyclophosphamide 
every 2 weeks followed by azathioprine (44 patients). At 
the end of follow-up, there were no signiﬁ  cant differences 
between renal outcomes with a non-signiﬁ  cant decrease in 
infections in patients on the lower dose of cyclophosphamide 
(Houssiau et al 2002; Houssiau et al 2004). Ten patients in 
the high-dose group developed severe infections compared 
with 5 in the low-dose group. Similar numbers of patients in 
both groups developed hematological and gonadal toxicity, 
although only 1 patient (in the high-dose group) developed 
premature menopause. The lack of any other difference in the 
adverse effects proﬁ  le was probably due to the small numbers 
in each group. It should be noted though that the majority 
of patients included in this study were Caucasian and had 
preserved renal function at the start of the trial; hence, these 
results may not be generalized to a non-Caucasian population 
with signiﬁ  cant renal impairment.
In addition to alternative cyclophosphamide regimens, 
other therapies were also sought and mycophenolate mofetil 
(MMF) has shown promise in this area. MMF is an immuno-
suppressant medication that was originally approved by the 
FDA in 1995 for prevention of renal transplant rejection and 
has been used in regimens for various other organ transplants. 
MMF was subsequently used in lupus nephritis initially in 
uncontrolled cohort studies, which were then followed by 
randomized controlled trials.
Review of the pharmacology
and mode of action of 
mycophenolate mofetil
MMF is the 2-morpholinoethyl ester derivative of mycophe-
nolic acid (MPA), a weak organic acid produced by several 
Penicillium species (Allison and Eugui 2000). MMF has 
excellent oral bioavailability of 94.1% in healthy volunteers 
(Bullingham et al 1998). After absorption, MMF is rapidly 
converted to its active metabolite, MPA by various plasma, 
liver and renal esterases. The half life of MPA is 17.9 hours 
in healthy volunteers and is 97%–98% bound to plasma pro-
teins, primarily albumin, although it is the unbound fraction 
that is pharmacologically active (Bullingham et al 1998 and 
Nowak and Shaw 1995). It is mostly excreted through the 
kidneys as its glucuronide (MPAG). Several factors includ-
ing renal dysfunction, hypoalbuminemia, accumulation of 
MPAG and hemoglobin levels have been shown to affect 
MPA pharmacokinetics and pharmacodynamics (Bullingham 
et al 1998, Nowak and Shaw 1995, van Hest et al 2006).Biologics: Targets & Therapy 2008:2(2) 299
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MMF has several effects on the immune system. The best 
described of these is its selective inhibition of inosine mono-
phosphate dehydrogenase (IMPDH), an enzyme involved in 
purine biosynthesis. IMPDH exists in two isoforms – type I, 
which is seen in most cell types and type II, which has greatly 
increased expression in activated lymphocytes (Natsumeda 
et al 1990). MMF inhibits the type II isoform nearly 5 times 
as much compared with the type I isoform, hence conferring 
its speciﬁ  city for activated lymphocytes (Carr et al 1993).
In addition to this, further speciﬁ  city is conferred by 
MMF’s mode of action. Two mechanisms exist for generation 
of purines (which are required to make up DNA and RNA) – 
the salvage pathway and the de novo pathway. Most cell 
types can employ either pathway but lymphocytes are unique 
in their complete dependence on the de novo pathway for 
purine synthesis. IMDPH is only absolutely required in the 
de novo pathway (Allison and Eugui 2000), thus resulting 
in a net decrease in DNA synthesis and inhibition of cellular 
proliferation predominantly in activated lymphocytes.
Apart from its effects on proliferation of activated 
lymphocytes, various other properties have been ascribed 
to MMF. In vitro data have shown that MMF inhibits the 
proliferation of ﬁ  broblasts and vascular smooth muscle cells 
(Morath et al 2006) as well as inhibiting collagen deposition, 
tubular cell proliferation, and interstitial ﬁ  brosis (Roos et al 
2007). In addition, MMF interferes with antibody production 
by B cells (Allison et al 1991) and adhesion molecule expres-
sion (Blaheta et al 1999), thus limiting the immune cell–cell 
interactions required for full activation. Dendritic cells, 
which are the principal cell responsible for activating naïve 
T cells, are also affected by MMF (Colic et al 2003), raising 
the hypothesis that MMF may contribute to inducing a state 
of immune tolerance towards previously reactive antigens 
(Lagaraine and Lebranchu 2003). MMF has also been thought 
to play a role in reducing inﬂ  ammation via suppression of 
inducible nitric oxide synthase (Senda et al 1995).
Animal models
MMF has been shown to improve outcomes in both the 
MRL/lpr and NZB × NZW F1 murine models of lupus 
nephritis. Eight-week-old MRL/lpr mice treated with 90 
mg/kg MMF daily had a reduced likelihood of developing 
albuminuria at 23 weeks (22 vs 88% in controls), histologi-
cally less severe glomerulonephritis, and less immunoglobu-
lin and C3 deposits in glomerular capillary walls compared 
with control mice (van Bruggen et al 1998). Three-month-
old MRL/lpr mice with established glomerulonephritis 
treated with 100 mg/kg MMF daily had prolonged survival, 
reduced incidence of hematuria and albuminuria, and reduced 
numbers of B cells and IgG anti-dsDNA antibodies compared 
with control mice (Jonsson et al 1999). The same study also 
demonstrated that cyclophosphamide had similar efﬁ  cacy to 
MMF treatment in that setting.
Improvements in disease outcomes have also been seen 
in the NZB × NZW F1 model. Three-month-old mice treated 
with MMF (60 mg/kg daily) until death were less likely to 
develop proteinuria, had improved renal function, and better 
survival than control mice (80% vs 50% alive at 9.5 months) 
(Corna et al 1997). In another study, MMF at a higher dose 
of 200 mg/kg daily resulted in 100% survival compared 
with 10% in controls, and also suppressed the development 
of albuminuria and anti-dsDNA antibodies (McMurray et al 
1998). Mice treated with MMF (100 or 30 mg/kg daily) from 
the age of 3 months (prior to renal immune complex deposi-
tion but at the time when serum autoantibodies are present) 
had improved survival compared with control (90% in 
both groups of MMF-treated mice vs 42% in controls at 
42 weeks) (Ramos et al 2003). Of note, direct inhibition of 
autoantibody production was only seen at the higher dose of 
MMF, whereas qualitative changes with a reduction in total 
and antigen-speciﬁ  c IgG2a were seen at the lower dose of 
MMF, suggesting that this might be one of the mechanisms 
resulting in disease amelioration.
MMF in combination with a cyclooxygenase-2 (COX-2) 
inhibitor has also been used in this model starting at the age of 
ﬁ  ve months, at the time of renal immune complex deposition 
(Zoja et al 2001). MMF alone (60 mg/kg daily) improved 
animal survival (93% vs 53% at 8 months, 67% vs 47% at 9 
months) and limited renal damage compared with control. 
These beneﬁ  ts were signiﬁ  cantly increased in the group of 
animals treated with a combination of MMF and the COX-2 
inhibitor, which was used due to the previous ﬁ  nding of 
increased COX-2 derived thromboxane-A2 in lupus nephritis, 
thought to contribute to renal injury.
In addition to the role of thromboxane-A2 in lupus 
nephritis, two groups of investigators have investigated the 
effects of MMF on inducible nitric oxide synthase (iNOS), 
which has been implicated in pathogenesis of lupus nephri-
tis through generation of excess nitric oxide. Beneﬁ  ts were 
seen in survival (Lui et al 2002), levels of proteinuria and 
histological severity in MMF-treated MRL/lpr mice (Yu et al 
2001; Lui et al 2002). Renal cortical levels of iNOS mRNA 
and urinary nitrate production were reduced in one study 
(Yu et al 2001) whereas the other study did not ﬁ  nd any dif-
ference in intrarenal nitric oxide production, iNOS protein 
and mRNA levels and urinary nitrite/nitrate production at Biologics: Targets & Therapy 2008:2(2) 300
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12 weeks although there was a transient decrease in urinary 
nitrite/nitrate production at 8 weeks (Lui et al 2002).
In summary, MMF has been shown to be beneﬁ  cial in 
murine models of lupus although its exact mechanism of 
action remains to be fully determined.
Clinical trials of mycophenolate 
mofetil in lupus nephritis
To date, there have been 8 published reports of 6 randomized 
controlled trials (2 in abstract form only) of the use of MMF 
in lupus nephritis (Chan et al 2000; Ye et al 2001; Contreras 
et al 2004; Flores-Suarez and Villa 2004; Chan et al 2005; 
Contreras et al 2005; Ginzler et al 2005; Ong et al 2005). 
There have also been a signiﬁ  cant number of cohort stud-
ies describing the use of MMF in SLE, although not all 
patients in these studies had lupus nephritis. There have also 
been 3 meta-analyses and systematic reviews analyzing the 
available data. It should be noted that when assessing these 
controlled studies, there are limitations in the quality of the 
data available. All of these studies were open label and had 
unblinded assessors. In addition, most trials did not use 
allocation concealment or an intention-to-treat analysis. 
This is reﬂ  ected in the Jadad (quality) scores for the trials 
of 2 or 3 (Walsh et al 2007).
There were also differences in the histology in the vari-
ous trials. All trials included patients with proliferative lupus 
nephritis (Class III and IV, although some only had patients 
with Class IV disease). Some of the studies included patients 
with membranous nephritis (with and without proliferative 
change) which has a different clinical course to proliferative 
nephritis and it is not clear how inclusion of these patients 
could affect trial results. There are also limited available data 
on the use of MMF purely restricted to Class V nephritis; 
this is discussed further below.
Chan et al randomized 21 Chinese patients with diffuse 
proliferative lupus nephritis (WHO Class IV) each to either 
oral cyclophosphamide (2.5 mg/kg/day) replaced by aza-
thioprine at 6 months or oral MMF 2 g daily for 6 months, 
followed by MMF 1 g daily for a further 6 months and then 
replaced by azathioprine (Chan et al 2000). All patients were 
also treated concurrently with prednisolone. Remission was 
deﬁ  ned by urinary protein excretion and creatinine clearance. 
81% of patients treated with MMF had complete remission 
and 14% had a partial remission compared with 76% and 
14% of patients treated with cyclophosphamide. Relapse 
rates were 15% and 11% respectively. The authors concluded 
that MMF and prednisolone were at least as effective as oral 
cyclophosphamide and prednisolone.
In a subsequent extended follow-up study, with a median 
follow-up of 63 months, they investigated the role of MMF 
in induction-maintenance of lupus nephritis (Chan et al 
2005). The original protocol using MMF was modiﬁ  ed to 
treatment with MMF 2 g daily for 6 months, followed by 
1.5 g daily for 6 months and then 1g daily. Further patients 
were also recruited, increasing total numbers to 32 patients 
in the MMF group and 30 patients in the cyclophospha-
mide-azathioprine group. Greater than 90% of patients in 
both groups had either a complete or partial response to 
induction treatment. Over the follow-up period, there was 
no signiﬁ  cant difference between the risk of relapse and 
relapse-free survival between those treated with cyclophos-
phamide and MMF and between those treated with MMF 
for 12 or greater than 24 months. This provided evidence 
that MMF and prednisolone was an effective treatment for 
induction-maintenance in lupus nephritis.
Criticisms levelled at the study have included the use 
of oral cyclophosphamide compared with MMF, when the 
standard of care is intravenous cyclophosphamide and the 
relatively high cumulative dose of cyclophosphamide. In 
addition, patients included in the study also only had mild 
renal impairment at worst and were drawn solely from a 
Chinese population.
Contreras et al investigated the role of MMF as a sequen-
tial therapy following induction with up to a maximum of 
seven monthly intravenous boluses of cyclophosphamide 
(0.5–1.0 g/m2 body surface area) (Contreras et al 2004; 
Contreras et al 2005). Fifty-nine patients with lupus nephritis 
(12 with WHO class III, 46 with class IV and 1 with class 
Vb) were randomized to 3-monthly intravenous cyclophos-
phamide, oral azathioprine (1–3 mg/kg daily), or oral MMF 
(500–3000 mg daily) following induction. In addition, all 
patients received corticosteroids. The study population 
comprised 30 Hispanic, 27 black, and 3 white patients. The 
event-free survival rate for a composite endpoint of death or 
chronic renal failure was signiﬁ  cantly higher in the MMF and 
azathioprine groups compared with the cyclophosphamide 
group and the rate of relapse-free survival was higher in the 
MMF group compared with the cyclophosphamide group. 
Five patients died (4 in the cyclophosphamide group, 1 in 
the MMF group) and 5 patients developed chronic renal 
failure (3 in the cyclophosphamide group and 1 each in 
the remaining 2 groups) during maintenance therapy. The 
authors concluded that short term therapy with intravenous 
cyclophosphamide followed by maintenance therapy with 
MMF or azathioprine was more effective than long-term 
therapy with intravenous cyclophosphamide.Biologics: Targets & Therapy 2008:2(2) 301
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However, the number of patients with longer-term data 
was limited with 27 patients followed to 36 months and only 
5 were followed to 72 months; thus providing limited data 
on the longer-term outcomes of MMF use in maintenance 
therapy.
In the largest published study of MMF in lupus nephri-
tis to date, Ginzler et al subsequently reported results of 
a 24 week non-inferiority trial comparing oral MMF (1 g 
daily, increased to 3 g daily) against monthly intravenous 
cyclophosphamide (0.5 g/m2 body surface area, increased 
to 1 g/m2) (Ginzler et al 2005). Seventy-one patients were 
randomized to MMF and 69 patients to cyclophosphamide 
and the primary endpoint of the study was complete remis-
sion (deﬁ  ned as normalization of abnormal renal measure-
ments and maintenance of baseline renal measurements) at 
24 weeks. A secondary endpoint was partial remission at 24 
weeks, deﬁ  ned as improvement of 50% of all abnormal renal 
measurements, without worsening of any measurement. Sev-
enty-nine patients were black with 28 Hispanic and 24 white 
patients. Twenty-two had WHO class III nephritis, 76 had 
class IV, and 27 had class V. In their study, 22.5% of patients 
receiving MMF compared with 5.8% of patients receiving 
cyclophosphamide had a complete remission. There was 
no signiﬁ  cant difference in patients who achieved a partial 
remission (29.6% in the MMF group compared with 24.6% 
in the cyclophosphamide group). The authors concluded that 
this demonstrated that MMF was superior at inducing remis-
sion compared with intravenous cyclophosphamide.
The patients in this study also had relatively well pre-
served renal function at the start despite more than 50% of 
patients having class IV nephritis. The question has also been 
raised as to why the study protocol used a slowly increasing 
dose of MMF as opposed to more aggressive therapy with 
gradual tapering. Activity and chronicity indices were not 
reported.
The remaining published randomized trial was under-
taken by Ong et al where they randomized patients to 
induction therapy with intravenous cyclophosphamide 
0.75–1 g/m2 body surface area (25 patients) or oral MMF 
2 g daily (19 patients) for 6 months, both with corticoste-
roids (Ong et al 2005). The primary endpoint was remis-
sion of lupus nephritis (combined partial and complete 
remission) at 6 months. Patients had either WHO class III 
or IV nephritis with or without membranous change; and 
were made up of 22 Malay, 20 Chinese, and 2 patients of 
other ethnicity. Similar numbers of patients in each group 
achieved remission (52% in the cyclophosphamide group 
and 58% in the MMF group) and complete remission 
(12% and 26% respectively). There was no statistical dif-
ference between the various groups. Attending physicians 
were free to prescribe their choice of immunosuppressive 
therapy after the initial 6-month period and this comprised 
azathioprine, ciclosporin, and further intravenous cyclo-
phosphamide. Further long-term follow-up data (up to 48 
months) showed no signiﬁ  cant differences in patient kidney 
survival between the two randomized groups. The authors 
concluded that MMF with corticosteroids was as effective 
as cyclophosphamide in induction therapy.
Similar to the Chan et al study, this study also did not 
include any patients of African, Caucasian, or Hispanic ori-
gin. It should be noted that in both the Ginzler et al and Ong 
et al studies, the primary outcome measure was remission 
(including improvement of proteinuria) at 6 months. In view 
of this, caution should be employed when interpreting the 
results as proteinuria can take a prolonged period of time to 
resolve in severe nephritis; and late-stage renal failure can 
occur beyond the 6-month period.
There are also two further randomized trials published 
in abstract form only. Ye et al randomized 90 patients with 
severe SLE (with one or more of lung, renal, central nervous 
system, hemolytic anemia or vasculitic complications) to 
either monthly intravenous cyclophosphamide for 6–12 
months or MMF 1.5 g daily tapered to 1 g daily at 3 months 
and 0.5–0.75 g daily after a further 3 months (Ye et al 2001). 
The WHO class was not stated in the abstract. MMF was 
found to signiﬁ  cantly improve clinical and laboratory param-
eters, although no direct comparison with cyclophosphamide 
was made in the abstract. There was, however, a signiﬁ  cant 
difference in the incidence of adverse effects (gastrointes-
tinal tract reactions, infection, leukopenia, hair loss, liver 
dysfunction, and menopause) in the MMF group. Flores-
Suarez randomized 10 patients with class IV or V nephritis 
to either MMF up to 2 g daily or monthly intravenous cyclo-
phosphamide (Flores-Suarez and Villa 2004). MMF was as 
effective as intravenous cyclophosphamide and signiﬁ  cantly 
more patients on MMF achieved partial remission. Infections 
appeared to be milder in the MMF group.
In addition to the randomized trials, there have been several 
uncontrolled open-label cohort studies describing the use of 
MMF for a variety of disease manifestations in SLE. These 
studies have been relatively small, with the majority having 
numbers generally ranging between 10 and 30 patients with 1 
single study describing a cohort of 86 patients. The cohort stud-
ies are listed in Moore and Derry 2006. Although most of these 
studies, showed improvement in the patients treated with MMF, 
it is difﬁ  cult to draw deﬁ  nitive conclusions as no comparison Biologics: Targets & Therapy 2008:2(2) 302
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with standard therapy was made. However, Moore and Derry 
did pool together data from these various studies in their meta-
analysis (discussed further below).
Due to the relatively small number of patients in studies 
to date and some of the uncertainties surrounding the use 
of MMF, the Aspreva Lupus Management Study (ALMS) 
was undertaken to contribute further data in both induction 
and maintenance therapies for lupus nephritis (Sinclair et al 
2007). The study recruited 370 multi-racial patients from 
approximately 100 centers worldwide. Patients enrolled 
were between 12 and 75 years of age with SLE diagnosed 
according to the revised American College of Rheumatol-
ogy criteria; and had a histological diagnosis of Class III, 
Class IV-S, or IV-G, or Class V lupus nephritis or a mixture 
of these within 6 months prior to randomization. In addi-
tion, participants had to have active nephritis deﬁ  ned as: 
proteinuria 1 g/24 hours or elevated serum creatinine 
(1.3 mg/dL) or active urinary sediment in patients with 
Class IV-S or IV-G disease; and proteinuria 2 g/24 hours 
or elevated serum creatinine (1.3 mg/dL) in patients with 
Class III or V disease. Patients were excluded if they were 
receiving continuous dialysis for more than 2 weeks prior to 
randomization or had received (or was due to receive) a renal 
transplant. Patients who also had induction or maintenance 
immunosuppressive therapy within 12 months or 2 weeks 
respectively were also excluded. The inclusion criteria were 
broader than previous trials and allowed for more severely 
ill patients to be recruited as well as investigating treatment 
of class V nephritis. It was also hoped that the ALMS study 
would provide additional information on the relevance of the 
histological classiﬁ  cation of lupus nephritis.
In the trial, patients were randomized to either oral MMF 
(target dose of 1.5 g bd) or intravenous cyclophosphamide 
(every 4 weeks for 6 infusions; starting at 0.75 mg/m2 for the 
ﬁ  rst month with subsequent doses at 0.5–1.0 mg/m2) for 24 
weeks of induction therapy; followed by re-randomization 
to either oral MMF (1 g bd) or oral azathioprine (2 mg/kg 
daily) for maintenance if they achieved treatment response. 
All patients also received a concomitant dose of oral steroids 
pre-deﬁ  ned by the trial protocol.
Results of the induction phase have now been reported 
in abstract form (Ginzler et al 2007). The study did not meet 
its primary objective of showing a superior response rate 
with MMF compared with intravenous cyclophosphamide. 
Overall, 56.2% (104/185) of patients on MMF and 53.0% 
(98/185) of patients on cyclosphosphamide had a response 
to treatment (deﬁ  ned as decrease in proteinuria and improve-
ment/stabilization in serum creatinine). These rates were 
not signiﬁ  cantly different. However, on further analysis by 
racial group, signiﬁ  cant differences in response rates were 
found: 147/370 patients reported themselves as Caucasian, 
123 patients were Asian, and 100 patients belonged to 
“other” – a group comprising mostly black and mixed-race 
patients. Across all racial groups, 131 patients described 
their ethnicity as Hispanic. Response rates for MMF and 
cyclophosphamide were similar for Caucasian and Asian 
patients; however, there were signiﬁ  cant differences for 
Hispanic patients (60.9% response with MMF vs 38.8% with 
cyclosphophamide) and those classiﬁ  ed as “other” (60.4% 
response with MMF vs 38.5% with cyclophosphamide). 
No differences at baseline between the various groups were 
found to explain this variation.
The rate of adverse events was similar between the two 
groups during the 24-week induction phase. There were 24 
withdrawals from the MMF group (12 due to infection) and 
13 from the cyclophosphamide group (4 due to infection). 
There were 9 deaths in the MMF group (7 due to infection) 
and 5 in the cyclophosphamide group (2 due to infection 
and 2 due to SLE).
Class V (membranous) lupus nephritis
Membranous lupus nephritis occurs in about 20% of patients 
with lupus nephritis and represents a distinct entity histo-
pathologically. Clinically, when compared with patients with 
proliferative lupus nephritis, patients with membranous lupus 
nephritis tend to frequently have nephrotic range proteinuria, 
with more variable and more slowly progressive loss of renal 
function. There can, however, be considerable overlap in the 
clinical features and membranous lupus nephritis can occur 
with proliferative nephritis (Austin and Illei 2005). At pres-
ent, there is limited evidence available on the best approach 
to treat membranous lupus nephritis. The relatively indolent 
course in membranous lupus nephritis had been the main 
argument against using potent immunosuppressants, although 
more recently, it has been noted that there are signiﬁ  cant 
risks associated with prolonged nephrotic syndrome. Conse-
quently, some have now contended that aggressive therapy 
should be considered to reduce nephrotic proteinuria to pre-
vent the long-term complications of cardiovascular disease 
as a result of dyslipidemia and pro-thrombotic tendency. 
Nonetheless, although there is greater acknowledgment of 
these risks, there remain few data on the long-term beneﬁ  ts 
and risks of treating membranous lupus nephritis with potent 
immunosuppressants (Austin and Illei 2005).
Several small uncontrolled observational studies of MMF 
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Spetie et al reported their experience of MMF in 13 consecutive 
treatment naïve patients with membranous lupus nephritis 
(12 had pure class V nephritis and 1 had class III and V), who 
had a mean 24-hour urine protein:creatinine ratio of 5.1 (Spetie 
et al 2004). These patients were treated with MMF (mean dose 
1173 mg daily) and prednisolone (mean dose 31 mg daily), 
in addition to other measures to reduce proteinuria (including 
an ACE inhibitor and/or anigotensin receptor blocker). Ten 
of their patients had achieved complete or partial remission at 
6 months and at the end of their study period (mean follow-up 
of 16 months), 9 patients were in complete remission and 11 
had protein:creatinine ratios of 0.8. During the 208 patient 
months of follow-up, the only serious complication was of 
histoplasma pneumonia in one patient.
In their retrospective study, Kapitsinou et al reported 
on their cohort of patients, 6 of whom had membranous 
nephropathy (3 with pure membranous nephropathy, 1 with 
additional focal proliferative change, and 2 with additional 
diffuse proliferative change) (Kapitsinou et al 2004). Patients 
were treated with MMF 1 g twice daily and steroids for a 
mean duration of 14.8 months; the mean duration of nephritis 
prior to MMF treatment was 75 months. Mean proteinuria 
decreased from 1.9 g to 1 g daily, although this was not 
signiﬁ  cant, and there was no signiﬁ  cant difference in mean 
creatinine clearance. Four of the group had treatment failure 
deﬁ  ned as no remission at the end of follow-up.
Karim et al subsequently reported on 10 patients with 
predominantly membranous lupus nephritis (6 with addi-
tional focal proliferative change and 4 with pure membranous 
change) showing a signiﬁ  cant improvement in urinary protein 
excretion and serum albumin (Karim et al 2005). Nine of the 
patients had received previous immunosuppression and all of 
them were on antihypertensive agents prior to starting MMF. 
Patients were treated with MMF (doses between 1 and 2.5 g 
daily) for a mean time of 18.8 months. 24-hour urine protein 
excretion reduced from a median 2.26 g to 0.66 g with a con-
comitant rise in serum albumin from a median of 29.5 g/L to 
33.5 g/L at the end of follow-up. Serum creatinine was not 
signiﬁ  cantly affected. During the study period, 2 patients had 
infectious complications, 5 had gastrointestinal symptoms, 
and 1 patient needed to discontinue MMF.
More recently, Kasitanon et al reported a retrospective 
series of 29 cases of membranous nephropathy treated with 
MMF, analyzing the differences between those with and 
without concurrent proliferative disease; something not 
reported in previous papers (Kasitanon et al 2008). Ten 
patients had pure membranous nephropathy and the remain-
ing 19 had mixed membranous and proliferative nephritis; 
all patients had not received any immunosuppression apart 
from oral steroids at the start of the study. Patients were 
treated with 2 g daily of MMF, increased to 3 g daily after 
a month if tolerated. Patients in the group with pure mem-
branous nephropathy were followed for a mean of 40.4 
months compared with 23.6 months in those with a mixed 
nephropathy. The authors found no signiﬁ  cant difference 
in renal outcomes between the two groups. At 12 months, 
4/10 patients with pure membranous nephropathy and 7/19 
patients with mixed nephropathy had achieved complete 
remission whereas 1/10 in the ﬁ  rst group and 2/19 in the 
second had a worsening of renal disease; the remainder of 
the patients had no change in disease status. Overall, about 
40% of their patients, particularly those with mild protein-
uria responded to MMF treatment. Three patients developed 
infective complications (lobar pneumonia and septic arthritis) 
with no cases of herpes zoster.
From the limited number of studies, it would seem that 
MMF has a degree of efﬁ  cacy in membranous lupus nephri-
tis, with some studies reporting greater success than others 
although the patient cohorts in them are not directly com-
parable. However, there are no head-to-head comparisons 
with other agents; the study by Ginzler et al did include 27 
patients with class V nephritis but no further sub-analysis 
of this group was published (Ginzler et al 2005). Until 
more trials are done in membranous nephritis, it is difﬁ  cult 
to comment at present on how MMF compares with other 
immunosuppressive therapies in this area.
Use of MMF in pediatric lupus nephritis
At present, there are no published controlled trials of the 
use of MMF in pediatric SLE. Fu and Liu described the use 
of MMF in two Chinese children with lupus nephritis who 
were refractory to previous cyclophosphamide and ciclo-
sporin therapy (Fu and Liu 2001). All clinical symptoms 
and serum autoantibodies had become negative after 11–12 
months of treatment. A case series of 11 children was also 
published in the same year (Buratti et al 2001). In that paper, 
patients had lupus nephritis refractory to treatment with high 
dose oral or intravenous prednisolone, cyclophosphamide 
and/or azathioprine and were treated with a mean dose 
of 22 mg/kg/day for a mean duration of 9.8 months. In 4 
patients with class V membranous lupus nephritis, renal 
function normalized although little effect was seen in the 
children with class IV proliferative glomerulonephritis. In 
addition, adverse events were seen in 8 out of 11 (73%) 
patients, including infections, leucopenia, nausea, pruritus, 
headache, and fatigue.Biologics: Targets & Therapy 2008:2(2) 304
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Pecoraro et al published an abstract of 14 children with 
lupus nephritis (mean age 12.4 years) with more than 3 g of 
proteinuria daily and normal renal function who were treated 
with IV methyprednisolone followed by MMF (mean dose 
29 mg/kg daily) and oral prednisolone for 2 years (Pecoraro 
et al 2005). Seven children had class IV nephritis and the 
remainder had a mixture of other types. Repeat renal biopsies 
were done after 2 years and the authors found a reduction 
in inﬂ  ammatory cells in all biopsies as well as resolution of 
proteinuria in all cases, without any signiﬁ  cant hematologic 
or gastrointestinal events.
In a retrospective study, Lau et al reported on 44 
predominantly African American children with a mean age 
at biopsy of 14.2 years (Lau et al 2006). Only ﬁ  ve patients 
in their cohort received MMF (1 with class III nephritis and 
2 each with class IV and V nephritis) and no further analysis 
by treatment was undertaken due to the small numbers of 
patients. However, the authors did note that those with class V 
nephritis did have a lower mean urine protein: creatinine ratio 
at 12 months than those treated with corticosteroids alone.
In a review, Adams et al however, noted that in their 
practise, MMF was less effective and was associated with 
more adverse events compared with quarterly intravenous 
cyclosphosphamide (Adams et al 2006). In addition, they had 
had no patients who had managed to maintain a cyclophos-
phamide-induced remission with MMF, although numerical 
data were not provided. This was thought to be due to poor 
compliance secondary to gastrointestinal side effects. They 
recommended that cyclophosphamide should continue to be 
used in children with class III or IV lupus nephritis. However, 
Paredes suggested that MMF could be considered for mild 
to moderate nephritis with preserved renal function where 
fertility was an issue and oral compliance could be ascer-
tained; while maintaining the use of IV cyclophosphamide 
for the most unwell children (Paredes 2007). In view of the 
paucity of data on the use of MMF in children, it would seem 
reasonable to take this approach at present until further trials 
are conducted.
Safety and tolerability
In general, MMF has been reported to be relatively well 
tolerated. The principal adverse effects include gastroin-
testinal symptoms particularly diarrhea, nausea and vomit-
ing and abdominal cramps. There is a suggestion that the 
gastrointestinal side effects may occur more frequently in 
the transplant setting compared with its use in inﬂ  amma-
tory disease (Goldblum 1993). Side effects typically occur 
early in the course of treatment and tend to decrease with 
continued use. Some of the strategies to reduce the incidence 
of gastrointestinal side effects include divided doses or 
administration of the drug with food. In addition, hematologic 
(primarily leucopenia) and infection-related adverse events 
have also been reported, although it is unclear if the data 
obtained from its use in the transplant setting can be directly 
extrapolated due to the higher immunosuppressive burden in 
transplant patients. Hence, to determine the side effect proﬁ  le 
in SLE it is necessary to evaluate the safety of MMF in trials 
speciﬁ  c for this condition.
In their trial, Chan et al reported that signiﬁ  cantly fewer 
patients treated with MMF developed infections that required 
antibiotic treatment (12.5% vs 40% for the cyclophospha-
mide-azathioprine group) or hospitalization (6.3% vs 30% for 
the cyclophosphamide-azathioprine group) (Chan et al 2005). 
The incidence of infection was 1 in 234.0 patient-months 
in the MMF group compared with 1 in 102.5 months in the 
cyclophosphamide-azathioprine group. Four patients in the 
cyclophosphamide-azathioprine group died or developed end 
stage renal failure compared with none in the MMF group, 
although this difference was not statistically signiﬁ  cant. 
Other adverse events that were signiﬁ  cantly lower in the 
MMF group were leucopenia (4 × 109/L), severe hair loss, 
and amenorrhea. There was no signiﬁ  cant difference between 
the two groups for gastrointestinal upset, withdrawal due to 
side effects, or infection with herpes zoster.
In the study by Contreras et al the authors concluded 
that MMF and azathioprine were safer than intravenous 
cyclophosphamide for long-term maintenance (Contreras 
et al 2004, 2005). Hospitalization rates were signiﬁ  cantly 
lower in the MMF and azathioprine groups (1 hospital-day 
per patient-year) compared with the cyclophosphamide group 
(10 hospital-days per patient-year). The rate of severe infec-
tions and total infections was lower in both the MMF and 
azathioprine groups compared with the cyclophosphamide 
group. There was also signiﬁ  cantly less amenorrhea (6% and 
8% vs 32%), nausea and vomiting when the MMF and aza-
thioprine groups were compared with the cyclophosphamide 
group. There were no signiﬁ  cant differences in the incidence 
of diarrhea or leucopenia between the various groups.
Ginzler et al also reported fewer hospitalizations and 
severe infections in their MMF group. 6/75 patients in the 
cyclophosphamide group developed severe infection (nec-
rotizing fasciitis, gram-negative sepsis, pneumonia and lung 
abscess) compared with 1/83 in the MMF group (relative 
risk [RR] of 0.36, p = 0.03) (Ginzler et al 2005). Amenor-
rhea occurred in 2 patients receiving cyclophosphamide and 
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uncommon with 5 patients in the MMF group and 14 patients 
in the cyclophosphamide group developing sustained lym-
phopenia. Diarrhea was more common in the MMF group, 
with 15 patients developing this compared with only 2 in the 
cyclophosphamide group.
Two deaths occurred in the cyclophosphamide group with 
none occurring in the MMF group. One of these deaths was 
due to a cerebral hemorrhage occurring shortly after the ﬁ  rst 
dose of cyclophosphamide and the second death occurred 
after 2 doses of cyclophosphamide and was reported to 
be due to active SLE and sepsis. A third patient who was 
assigned to cyclophosphamide treatment declined therapy 
and subsequently died.
The study by Ong et al unlike the previous three trials 
reported no signiﬁ  cant difference in their rate of adverse 
events at 6 months (Ong et al 2005). There was no difference 
between the rates of infections, with 3 patients in each group 
developing pneumonia or septicemia and another 3 patients 
developing herpes zoster. There was also no difference in 
the rates of diarrhea. Of patients in the cyclophosphamide 
group, 52% developed leucopenia (3.5 × 109/L) compared 
with 36.8% of patients on MMF although this was not 
statistically signiﬁ  cant. A single patient in the cyclophos-
phamide group developed amenorrhea and another patient 
discontinued therapy due to persistent leucopenia. At the 
end of the follow-up period of 36 months, there had been 1 
death in each group.
It should be noted that in the transplant setting, however 
there have been reports of increased infection rates with 
herpesviruses, associated with MMF use. Most of the data 
available on this are on cytomegalovirus (CMV) infection; 
and the results have been conﬂ  icting, although overall MMF 
does seem to be associated with a modest increase (Wang 
et al 2004; Song et al 2006). It is unclear whether this increase 
is due speciﬁ  cally to MMF use or whether it represents 
overall immunosuppressive burden. A similar increase has 
not been noted in the studies of lupus nephritis, where over-
all immunosuppressive burden is lower. There are limited 
controlled data on the other herpes viruses, although there 
is a suggestion that herpes zoster occurs more frequently in 
liver transplant recipients, but not other organ transplants 
(Gourishankar et al 2004).
Enteric-coated mycophenolate sodium
In view of the frequent gastrointestinal side effects with 
MMF, an alternative enteric coated mycophenolate sodium 
preparation has been introduced. In the renal transplant 
setting, trials have shown equivalent safety and efﬁ  cacy to 
conventional MMF (Salvadori et al 2004; Budde et al 2006) 
with a reduced incidence in gastrointestinal-symptom burden 
(Chan et al 2006). There is only a single observational study 
on the use of mycophenolate sodium in lupus nephritis, with 
16 patients receiving this as induction therapy (Kitiyakara 
et al 2008). Eight of them achieved complete remission and 
4 had a partial remission. Gastrointestinal side effects were 
reported to be low, although there was no direct control group. 
However, despite the lack of speciﬁ  c data in lupus nephritis, 
there is no reason to expect that this would be signiﬁ  cantly 
different from the ﬁ  ndings in the transplant setting.
Pregnancy and lactation
One of the factors limiting the use of MMF is its teratogenicity. 
MMF has been shown to cause fetal malformations in rats 
and rabbits, resulting in cardiovascular, renal, and central 
nervous system defects, in the absence of maternal toxicity 
at doses equivalent to half or less of the recommended treat-
ment dose (EMEA 2008). Fetal malformations in humans 
have also been reported, although no controlled trial data 
are available. There had been no clear pattern of malforma-
tions noted, although a recent report suggesting a possible 
characteristic phenotype with cleft lip and palate, microtia 
with atresia of the external auditory canal, micrognathia, 
and hypertelorism has been published (Perez-Aytes et al 
2008). In view of its teratogenicity, the product data sheet 
states mycophenolate is currently not recommended for 
use in pregnancy and effective contraception needs to be 
maintained while on treatment and for up to 6 weeks after 
discontinuation (EMEA 2008).
MMF has also been shown to be expressed in the breast 
milk of lactating rats, although there are no data in humans. 
Consequently, the manufacturer has advised avoidance of 
MMF in breastfeeding mothers (EMEA 2008).
Meta-analyses and systematic 
reviews
In general, studies conducted on lupus nephritis have been few 
and relatively small. The total number of patients recruited in 
the 6 randomized studies described above was 370. In addition, 
there are only about 200–300 patients in randomized studies 
involving cyclophosphamide and azathioprine (Flanc et al 
2004), the most widely used therapies at present. Consequently, 
meta-analyses are limited as the studies available for inclusion 
are small, short-term, and of limited methodological quality. 
Nonetheless based on available data, 3 meta-analyses on the use 
of MMF in lupus nephritis have been published to date (Moore 
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Moore and Derry used 5 of the randomized studies (Chan 
et al 2000, 2005; Contreras et al 2004, 2005; Flores-Suarez 
and Villa 2004; Ginzler et al 2005; Ong et al 2005) totalling 
306 patients, deemed to have sufﬁ  cient data for analysis 
(Moore and Derry 2006). They pooled data from all these 
studies to calculate the efﬁ  cacy rates (deﬁ  ned by complete 
response, complete or partial response and subsequent 
relapse) and adverse event rates (death, hospital admission, 
adverse events discontinuation, all infections, serious infec-
tions, leucopenia, amenorrhea, hair loss, and diarrhea). No 
distinction was made between studies investigating the use 
of MMF in induction, maintenance or both. They found that 
MMF was signiﬁ  cantly more likely to result in a complete 
response (36% of patients vs 23% with cyclophosphamide, 
relative beneﬁ  t 1.5) and complete or partial response (66% 
of patients vs 54% with cyclophosphamide, relative beneﬁ  t 
1.2) than cyclophosphamide. There was no signiﬁ  cant dif-
ference between the two therapies for risk of subsequent 
relapse. They calculated that the number needed to treat 
with MMF was 7.6 (95% conﬁ  dence interval [CI] 4.2–43) 
for one additional complete response and 8.0 for 1 additional 
complete or partial response.
The combined data for all randomized trials also showed 
a signiﬁ  cantly lower incidence of death (0.7% with MMF vs 
7.8% with cyclophosphamide; with 1 less death occurring for 
every 14 patients treated with MMF). Other adverse events 
that occurred signiﬁ  cantly less frequently with MMF were 
all infections, serious infections, leucopenia, amenorrhea and 
hair loss. Diarrhea occurred signiﬁ  cantly more frequently 
with MMF (16% vs 4% with cyclophosphamide, RR 4.0). 
There were no signiﬁ  cant differences between the rates of 
discontinuation due to adverse events.
In addition to the randomized trials, the authors also 
identiﬁ  ed 11 fully published cohort studies and a further 7 as 
abstracts. The amount of data reported in these studies was 
variable and of these, only 10 studies treated patients solely 
for lupus nephritis. In addition, only 5 of these documented 
histology on biopsy, whereas the rest used deteriorating 
renal function, rising dsDNA titers, or inadequate control on 
standard immunosuppression. Complete or partial response to 
therapy was reported in only 7 of those studies, giving a total 
of 151 patients. Of those patients, 121 (80%) had a complete 
or partial response following treatment with MMF. Overall, 
there was a 14% rate for discontinuation due to adverse events 
and a 10% rate of discontinuation due to lack of efﬁ  cacy. All 
infections were common, affecting 23% of patients but serious 
infection occurred in only about 4%. Gastrointestinal events 
affected about 30% of patients and there was no occurrence 
of amenorrhea. There was only a single death (after serious 
infection) reported in all the cohort studies.
Zhu et al, in another meta-analysis, utilized only data 
from the 3 published trials (and not the abstract by Flores-
Suarez et al 2004) comparing MMF with cyclophosphamide 
for induction treatment of lupus nephritis (Zhu et al 2007). 
They found no signiﬁ  cant difference between the rates of 
MMF or cyclophosphamide to induce complete remission, 
partial remission and overall remission. MMF was signiﬁ  -
cantly less likely to cause infection (RR 0.65). There was a 
non-signiﬁ  cant decrease in amenorrhea (RR 0.22, 95% CI 
0.04–1.22) and leucopenia (RR 0.61, 95% CI 0.37–1.03) with 
MMF. MMF was also more likely to cause gastrointestinal 
symptoms, but again this did not reach statistical signiﬁ  cance 
(RR 1.33, 95% CI 0.97–1.84). There was also no signiﬁ  cant 
difference between the risk of developing end-stage renal 
failure or death between those treated with MMF and cyclo-
phosphamide at induction.
They further performed a sensitivity analysis by exclud-
ing the Chan trial as it had used oral cyclophosphamide for 
induction. This was on the basis that oral cyclophosphamide 
differed from intravenous cyclophosphamide in some of its 
effects. On exclusion of this trial, Zhu et al then found that 
the rate of complete remission was signiﬁ  cantly higher in the 
MMF group (relative beneﬁ  t 3.10, 95% CI 1.38–7.01) and 
that the incidence of leucopenia was signiﬁ  cantly lower. They 
did not ﬁ  nd any difference in the remaining results.
In addition, Zhu et al also analyzed the trials that com-
pared MMF with azathioprine for maintenance treatment of 
lupus nephritis. They found no signiﬁ  cant difference between 
MMF and azathioprine with regard to the incidence of death, 
end stage renal failure, disease relapse and doubling of serum 
creatinine. There was a higher incidence of gastrointestinal 
symptoms in the MMF group, but a lower incidence of 
leucopenia.
In the most recent meta-analysis, Walsh et al again com-
pared only the studies that randomized patients for induction 
therapy (Walsh et al 2007). They utilized the studies analyzed 
by Zhu et al as well as the abstract published by Flores-Suarez 
et al 2004, giving a total of 268 patients. They noted that 3 
out of the 4 studies failed to show any signiﬁ  cant difference 
in induction of remission but that the pooled data showed 
a RR of 0.70 (95% CI 0.54–0.90) for failure of MMF to 
induce remission compared with cyclophosphamide. They 
also analyzed a composite outcome of death or end-stage 
renal failure. This showed a non-signiﬁ  cant difference at 
the end of the prespeciﬁ  ed study duration, although the RR 
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(RR 0.35, 95% CI 0.10–1.22). However, on using extended 
follow-up data, this lower risk with MMF was signiﬁ  cant 
(RR 0.44, 95% CI 0.23–0.87).
Walsh et al also concluded that in general there were too 
few adverse events for most categories to perform analysis, 
apart from infection, which had a non-signiﬁ  cantly lower 
risk for MMF (RR 0.64, 95% CI 0.39–1.06). Of patients on 
cyclophosphamide, 6/106 developed amenorrhea compared 
with none on MMF.
Quality of life and economic issues
Treatment for lupus nephritis has signiﬁ  cant cost implica-
tions; both in terms of the cost of the medication as well as 
ancillary factors (eg, staff time and costs, use of available 
beds). In addition, both the disease and treatment can signiﬁ  -
cantly affect quality of life. There are unfortunately minimal 
data in this area with only 1 economic model and 1 quality 
of life study published.
Wilson et al developed a model simulating the costs and 
outcomes of treating a patient with lupus nephritis with either 
intravenous cyclophosphamide (dosing schedule based on 
Ginzler et al 2005; Ong et al 2005) or MMF (mean dose of 
2.7 g daily, based on trial doses between 1–3 g daily) (Wil-
son et al 2007). Costs were based on the 2005 price-year for 
the National Health Service (NHS) in the UK. Their results 
showed that MMF was the less costly induction strategy, 
costing £1,388 over the 24-week period, compared with 
£2,994 for cyclophosphamide. In addition, treatment with 
MMF resulted in superior quality of life with 0.26 QALYs 
compared with 0.22 for cyclophosphamide. Tse et al pub-
lished the only available study of a quality of life comparison 
between MMF and cyclophosphamide treatment for lupus 
nephritis (Tse et al 2006). This was in 12 patients and overall, 
MMF treatment was associated with higher domain scores in 
both the instruments used (SF36 and WHOQOL).
Both these studies have limitations. The economic model 
uses inferred rather than directly measured quality of life 
data to derive QALYs, aggregates data from randomized 
controlled trials of limited quality to generate models that 
might not necessarily be representative of long-term costs 
or directly obtained health resource utilization; and uses 
predominantly US treatment data with UK economic costing 
data. The quality of life study was retrospectively done in a 
small group of patients where there are insufﬁ  cient data to 
draw any deﬁ  nitive conclusions about the efﬁ  cacy of MMF 
vs cyclophosphamide.
It has also been suggested that a reduced side effect 
rate and improved quality of life with MMF might improve 
compliance (Tse et al 2006), but there are no direct data 
comparing this between the two agents. It is possible that 
compliance could be more challenging with long-term daily 
oral medication, as opposed to intermittent intravenous 
cyclophosphamide in a hospital/clinic setting. Particularly in 
adolescent patients, it has been noted that some physicians 
might be reluctant to entrust them with responsibility for 
their induction treatment (Paredes 2007).
In summary, good quality data are still much needed with 
respect to cost effectiveness, quality of life and compliance 
issues.
Unresolved questions
Use in severe renal impairment
There are very limited data on the use of MMF in lupus 
nephritis where renal impairment is severe. All major trials 
to date excluded patients with severe renal impairment and, 
consequently, it will be of interest to see the ﬁ  nal results 
from the Aspreva Lupus Management Study which excluded 
only patients on dialysis but not others with severe renal 
impairment.
Long-term data
Compared with the 20–30 years of experience with intra-
venous cyclophosphamide, there are limited available data 
on the longer-term outcomes and safety proﬁ  le of MMF. 
Although short-term data on MMF are generally favorable, 
further studies are required to delineate the longer-term 
relapse rates and risk of renal disease progression while 
on MMF immunosuppression especially as end-stage renal 
failure can occur up to 5–10 years after diagnosis.
MMF dosing
At present, the optimal dose of MMF and the duration of 
induction therapy are unknown. The 6-month induction 
phase used in most studies is derived from the experience 
with intravenous cyclophosphamide. However, few data are 
available to indicate if 6 months of therapy is ideal or whether 
a more prolonged period would be appropriate depending on 
response to therapy.
In addition, the dose of MMF in trials was not modi-
ﬁ  ed depending on levels of free MMF in plasma. There are 
multiple factors associated with lupus nephritis (eg, hypo-
albuminemia, renal impairment, concomitant medication, 
hemoglobin) which can affect the pharmacokinetics. In the 
transplantation setting, there are data to suggest that MMF 
levels are associated with efﬁ  cacy and safety (van Gelder et al 
1999; Weber et al 2002; Le Meur et al 2007). Studies in the Biologics: Targets & Therapy 2008:2(2) 308
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transplant setting have also reported that increased plasma 
levels of MMF correlated with hematological, infectious and 
gastrointestinal side effects, although there were differences 
depending on which pharmacokinetic parameter was used 
(reviewed in van Gelder and Shaw 2005).
There are limited data about measurement of MMF 
plasma levels in lupus nephritis at present, although it would 
seem reasonable to extrapolate the data from the transplant 
setting which suggests that therapeutic drug monitoring of 
MMF is likely to be of beneﬁ  t. Further studies, though, are 
currently underway in the transplant setting to determine 
more exactly the advantages of MMF monitoring.
Conclusion
Lupus nephritis represents a signiﬁ  cant complication of SLE 
with substantial morbidity and mortality. Although treatment 
has improved, the current standard of therapy with cyclophos-
phamide is associated with signiﬁ  cant morbidity, including 
an increased risk of serious infections and amenorrhea. 
MMF has emerged as a potential alternative treatment, both 
in induction and maintenance therapy for lupus nephritis. 
However, the randomized trials and cohort studies published 
to date have all reported on small numbers of patients, with 
the largest study including 140 patients. Only 1 random-
ized controlled study showed that MMF was statistically 
superior to cyclophosphamide for induction. The remainder 
of the controlled trials did show slightly better results with 
MMF compared with cyclophosphamide but due to the small 
numbers of patients recruited, none were sufﬁ  ciently powered 
to demonstrate a signiﬁ  cant difference, lending credence to 
the suggestion that MMF might be superior to cyclophos-
phamide. Unfortunately, the induction phase of the ALMS 
study which has recently been reported has not contributed 
further knowledge to the discussion as to whether MMF is 
or is not superior to cyclophosphamide, although the data 
from the maintenance phase are now awaited.
One point of note is that these trials included a signiﬁ  cant 
number of non-Caucasian patients, raising the possibility 
that their results might have greater general application. In 
view of these small studies, several meta-analyses have been 
carried out. Again, these showed varying results depending 
on which trials were included in the meta-analysis, although 
they all suggest that MMF is at least as effective if not more 
so than cyclophosphamide. For adverse events, again there 
are difﬁ  culties in making deﬁ  nitive conclusions due to the 
small numbers, although it would seem that treatment with 
MMF was less likely to result in death, signiﬁ  cant infection, 
amenorrhea, or leucopenia than cyclophosphamide, although 
these differences did not always reach statistical signiﬁ  cance. 
Diarrhea appeared to be more common with MMF.
A limited number of studies have investigated the quality 
of life and economic beneﬁ  ts associated with MMF compared 
with cyclophosphamide. These have been favorable, although 
of limited quality with small numbers of patients and limited 
data available for modeling. Nonetheless, MMF would be 
expected to result in better quality of life for patients in view 
of its possible reduced adverse event proﬁ  le.
It would seem that so far, MMF represents a potential 
development for the treatment of lupus nephritis, although 
several questions remained unanswered. No comparison 
has been made with MMF and the low-dose intravenous 
cyclophosphamide regimen (Houssiau et al 2002), which 
has been shown to be as efﬁ  cacious as the high-dose regimen 
with potentially fewer side effects. In addition, the studies 
on MMF published to date have been relatively small with 
limited follow-up duration, making it difﬁ  cult to assess the 
effect of MMF on the clinically important outcomes of death 
and end-stage renal disease. Longer-term data and experience 
with MMF are deﬁ  nitely still needed to fully assess what role 
it will play in the management of lupus nephritis.
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